Glucotrack Publishes Peer-Reviewed Study Validating Long-Term Accuracy of Continuous Blood Glucose Monitor

summarizeSummary

Glucotrack announced the publication of a peer-reviewed study validating the long-term accuracy and stability of its continuous blood glucose monitoring (CBGM) technology, a key milestone for its FDA submission pathway.

check_boxKey Events

• Peer-Reviewed Study Published

  Glucotrack announced the publication of a scientific article in The Journal of Diabetes Research, providing external validation for its continuous blood glucose monitoring (CBGM) technology.

• Strong Preclinical Results

  An in-vivo ovine study demonstrated a weighted average Mean Absolute Relative Difference (MARD) of 6.8% over periods of up to 240 days, indicating excellent accuracy and consistent performance, with no device-related adverse safety events.

• Supports FDA Submission

  The positive long-term accuracy and stability data reinforce the company's confidence in the CBGM platform's design and are crucial for advancing towards an Investigational Device Exemption (IDE) submission with the FDA.

auto_awesomeAnalysis

Glucotrack, a medical technology company, announced the publication of a peer-reviewed study demonstrating the long-term accuracy and stability of its continuous blood glucose monitoring (CBGM) technology. The in-vivo ovine study showed a strong Mean Absolute Relative Difference (MARD) of 6.8% over 240 days with no adverse events. This external validation is a critical step for the company, reinforcing confidence in its platform's design and supporting its progression towards an Investigational Device Exemption (IDE) submission with the FDA. For a micro-cap company like Glucotrack, positive preclinical data is highly significant, as it de-risks the core technology and strengthens the path to commercialization.